The company's net profit was at Rs 1,182 crore, with revenue at Rs 5,633 crore and EBITDA margin rising to 26.7 percent, in ...

Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 970 in its research report ...

Ahmedabad-based Zydus Lifesciences Ltd has registered a decline of around 1% in net profit at Rs. 1,170.9 crore during the last quarter of FY25, as compared to Rs. 1,182.3 crore in the same period a ...

Zydus Lifesciences Ltd. reported growth in the fourth quarter of fiscal 2025, driven by higher non-recurring components in ...

Zydus Lifesciences reported a 17.3% increase in FY25 consolidated net profit, reaching Rs 4,525.5 crore, driven by strong US ...

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

Results: Zydus Lifesciences Q4FY25 net profit dips 1% to Rs 1,244 crore due to exceptional charge; revenue grows 17% to Rs ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Zydus Lifesciences Limited announced a notable 19% increase in revenue for FY25, with net profits rising to Rs. 47,451 mn.

Indian drugmaker Zydus Lifesciences reported a higher adjusted fourth-quarter profit on Tuesday, driven by new drug launches in the U.S., its biggest market.

The consolidated net profit of Zydus Lifesciences Ltd for the fourth quarter of financial year 2025 dropped marginally to ...